• Publications
  • Influence
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
A prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials offered clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population. Expand
Edoxaban versus warfarin in patients with atrial fibrillation.
Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. Expand
Oral apixaban for the treatment of acute venous thromboembolism.
A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding. Expand
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer.
The combination of a score < or =4.0 by the authors' simple clinical prediction rule and a negative SimpliRED D-Dimer result may safely exclude PE in a large proportion of patients with suspected PE. Expand
Low-molecular-weight heparins.
  • J. Weitz
  • Medicine
  • The New England journal of medicine
  • 4 September 1997
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Three parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in HIT patients and fondaparinux binds only to antithrombin; therefore, HIT and osteoporosis are unlikely to occur. Expand
Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Three additional parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in patients with HIT, and fondaparinux-associated HIT or osteoporosis is unlikely to occur. Expand
Apixaban for extended treatment of venous thromboembolism.
Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thromboprophylactic dose (2.5mg) reduced the risk of recurrent venous thromboembolism without increasing the rate of major bleeding. Expand
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
The two agents in the most advanced stages of development are dabigatran etexilate and rivaroxaban, which inhibit thrombin and FXa, respectively, which renders them more convenient than VKAs. Expand
Use of a Clinical Model for Safe Management of Patients with Suspected Pulmonary Embolism
The optimal strategy for investigating patients with suspected pulmonary embolism should combine clinical assessment, ventilation-perfusion scanning, and venous ultrasonography of the lower extremities, and the group developed a useful clinical model by reviewing the literature and coming to a consensus on a scoring system. Expand